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ttp://dx.doi.org/10.1016/j.ajpath.2014.08.008Inhalational anthrax is caused by inhalation of Bacillus anthracis spores. The ability of B. anthracis to
cause anthrax is attributed to the plasmid-encoded A/B-type toxins, edema toxin (edema factor and
protective antigen) and lethal toxin (lethal factor and protective antigen), and a poly-D-glutamic acid
capsule. To better understand the contribution of these toxins to the disease pathophysiology in vivo,
we used B. anthracis Ames strain and isogenic toxin deletion mutants derived from the Ames strain to
examine the role of lethal toxin and edema toxin after pulmonary spore challenge of cynomolgus
macaques. Lethal toxin, but not edema toxin, was required to induce sustained bacteremia and death
after pulmonary challenge with spores delivered via bronchoscopy. After intravenous challenge with
bacilli to model the systemic phase of infection, lethal toxin contributed to bacterial proliferation and
subsequent host death to a greater extent than edema toxin. Deletion of protective antigen resulted in
greater loss of virulence after intravenous challenge with bacilli than deletion of lethal toxin or edema
toxin alone. These ﬁndings are consistent with the ability of antieprotective antigen antibodies to
prevent anthrax and suggest that lethal factor is the dominant toxin that contributes to the escape of
signiﬁcant numbers of bacilli from the thoracic cavity to cause anthrax after inhalation challenge with
spores. (Am J Pathol 2014, 184: 3205e3216; http://dx.doi.org/10.1016/j.ajpath.2014.08.008)Supported by National Institute of Allergy and Infectious Diseases grant
P01 AI056295 (C.R.L., M.F.L., J.A.L., and J.A.H.).
Disclosures: None declared.
Current address of T.B., Department of Microbiology and Immunology,
The University of Texas Medical Branch, Galveston, TX; of M.F.L. and
C.R.L., Center for Infectious Disease, Colorado State University, Fort
Collins, CO.Inhalational anthrax, caused by inhalation of Bacillus
anthracis spores, is the most lethal form of anthrax, often
causing death within days of exposure. After pulmonary spore
challenge, infection occurs in three phases: an invasion phase,
in which lung and lymphatic vessel invasion is mediated by
spore-laden phagocytes and possibly free spores; followed by
a proliferation phase, in which bacilli proliferate in the drain-
ing lymphatic vessels and lymph nodes; and ﬁnally a terminal
septicemic phase, in which bacteria disseminate hema-
togenously and proliferate in the blood and other organs.1
Death frequently occurs with massive bacteremia without
the development of primary pneumonia.
The ability of B. anthracis to cause anthrax has been attrib-
uted primarily to plasmid-encoded virulence factors that consist
of a poly-D-glutamic acid capsule (plasmid pX02) and two
A/B-type toxins, lethal toxin (LT) and edema toxin (ET)
(plasmid pX01). The capsule inhibits macrophage phagocytosisstigative Pathology.
.of vegetative bacilli in vitro and may inhibit the humoral im-
mune response in vivo.2e4 The toxins are thought to exert their
effects locally within phagosomes soon after spore germination,
as well as at a distance in the systemic circulation.5e9 Protective
antigen (PA), the toxin component common to both LT and ET,
is the cell-binding subunit that binds to ubiquitous receptors on
multiple cell types. LT is composed of PA and lethal factor
(LF), whereas ET is composed of PA and edema factor (EF).
Proteolytic cleavage of PA (83 kb) into 20-kb and 63-kb frag-
ments, either on the cell surface or in body ﬂuids, leads to
Hutt et alheptamerization of the 63-kb PA fragment and formation of a
prepore on the cell surface, with subsequent competitive bind-
ing to three molecules of LF, EF, or both.10e17 Endocytosis of
the receptor complexes followed by acidiﬁcation within the
endosome results in a conformational change in the prepore,
with subsequent delivery of the enzymatic moieties into the
cytoplasm, where they exert their effects on the cell.18 LT is a
zinc metalloproteinase that cleaves mitogen-activated protein
kinases, and ET is an adenylate cyclase that increases cyto-
plasmic cAMP.19e21
Much of our current knowledge about the effects of
B. anthracis toxins is derived from in vitro experiments or
from challenge of animals with puriﬁed toxins (reviewed by
Moayeri and Leppla22). In rodents challenged with lethal
doses of puriﬁed toxins, evidence increasingly points to the
systemic effects of LT and ET on the heart and vasculature
with subsequent alterations in hemodynamic parameters as
a primary pathogenic mechanism that leads to toxin-
induced death in susceptible strains.23e26 However, in-
teractions between the host and the infectious organism are
more complex than what occurs after challenge with puri-
ﬁed toxin. The outcome after pulmonary challenge with
spores ultimately depends on host susceptibility to all of the
virulence factors and their expression and activity at the
appropriate stage of infection. Thus, in vitro experiments or
experiments in animals using puriﬁed toxins may not
accurately represent the role of the toxins after challenge
with fully virulent spores.
To examine the role of anthrax toxins after pulmonary
challenge with B. anthracis spores, we initially examined the
virulence of isogenic toxin deletion mutants (PA, LF, and
EF) of a fully virulent strain of B. anthracis in BALB/c
mice after intratracheal inoculation with spores. Systemic
dissemination and lethality of the toxin deletion mutants in
BALB/c mice were similar to the parental strain because of
the high susceptibility of mice to capsule.27,28 Next we
examined the virulence of isogenic capsule and toxin deletion
mutants of B. anthracis, Ames strain, in New Zealand white
rabbits and found that intrapulmonary delivery of capsule-
negative or PA deletion mutant spores resulted in complete
loss of virulence.29 Furthermore, elimination of each toxin
alone by deletion of EF or LF individually resulted in a
decrease in virulence for each of the mutants as indicated by
an increase of 100-fold in the LD50 compared with the
Ames strain. Absence of either LT or ET resulted in reduced
dissemination and/or survival of vegetative bacilli outside the
thoracic cavity. A similar reduction in virulence was
observed after i.v. injection of vegetative bacilli of the PA,
EF, and LF deletion mutants compared with the Ames strain.
Dependence on PA for virulence after subcutaneous and
intranasal spore challenge in New Zealand white rabbits was
also recently reported using toxin deletion mutants of the
virulent Vollum strain.30,31 In guinea pigs, however, deletion
of PA, LF, and EF was not sufﬁcient to abolish virulence.
Thus, the importance of particular B. anthracis virulence
factors appears to vary among host species.3206Nonhuman primates (NHPs) are increasingly used as an-
imal models to evaluate new vaccines and therapeutics for
inhalational anthrax, many of which target speciﬁc
B. anthracis virulence factors. Therefore, understanding the
effect of these virulence factors on B. anthracis pathogenesis
in NHPs is essential. B. anthracis, Ames strain, and isogenic
toxin deletion mutants were used to examine, for the ﬁrst time
in an NHP model, the role of each of the individual toxin
components in cynomolgus macaques after pulmonary
challenge with spores. Previous studies found that cyn-
omolgus macaques challenged with aerosolized B. anthracis
spores are an appropriate model of human inhalational
anthrax.32,33 In addition, cynomolgus macaques are
increasingly being used to test vaccines and therapeutics
against anthrax. Therefore, using the cynomolgus macaque
NHP model, we examined the role of the toxins after pul-
monary spore challenge. We also studied the role of toxins
during a synchronized systemic phase of infection, bypassing
the lung and draining lymph nodes, by intravenously
infecting cynomolgus macaques with vegetative bacilli.
Materials and Methods
B. anthracis Strains
The Ames strain of B. anthracis was obtained from the US
Army Medical Research Institute of Infectious Diseases
(Frederick, MD). Isogenic toxinedeﬁcient mutants for EF,
LF, and PA were constructed on the Ames parental strain by
replacing the cya coding sequence (62 bp upstream from the
translational start site to 104 bp downstream from the trans-
lational stop site), the lef coding sequence (167 bp upstream
from the translational start site to 59 bp upstream from the
translational stop site), or the pagA coding sequence (87 bp
downstream from the translational start site to 1383 bp
upstream from the translational stop site) (http://www.ncbi.
nlm.nih.gov/nuccore, accession number NC_001496.1),
respectively, with an omega-kanamycin resistance gene
cassette to help with screening of the mutants.28,34 The toxin-
deﬁcient phenotypes were conﬁrmed by Western blot ana-
lyses of supernatants from cultures grown under conditions
that promote toxin and capsule synthesis. Deletions of toxin
component genes were conﬁrmed using quantitative RT-PCR
assay (TaqMan assay; Applied Biosystems, Carlsbad, CA).
Growth curves for cultures of the mutant strains were similar
to the Ames strain.
Spore Preparation
Spore stocks were streaked onto a nutrient broth yeast agar
plate supplemented with sodium bicarbonate (NBY-NaCO3)
plates and incubated overnight at 37C. A few single colonies
were then added to 50 mL of phage assay medium in a
500-mL ﬂask. The culture was shaken at 250 rpm and
incubated for 5 to 7 days at 30C. Samples were viewed with
a 100 objective to determine the proportion of phase-brightajp.amjpathol.org - The American Journal of Pathology
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kill any remaining vegetative cells. Spores were collected by
centrifugation for 30 minutes at 16,000 g and washed three
times before being resuspended in sterile phosphate-buffered
saline (PBS). The suspensions were aliquoted and frozen
at 80C. The titers of individual aliquots were determined
by serial dilution and plating using an Autoplate 4000 (Spiral
Biotech, Bethesda, MD). Challenge material was prepared by
diluting the working stock spores in sterile PBS to provide
the desired target concentration. All dilutions were per-
formed in sterile PBS/0.01% Triton X-100 to minimize spore
clumping.
Preparation of Vegetative Cells for Intravenous
Infections
Vegetative cultures were prepared as previously described.28
Brieﬂy, a B. anthracis spore stock was used to streak NBY-
NaHCO3 to a ﬁnal concentration of 0.8% and kanamycin (50
mg/mL), when appropriate, and incubated in 5% CO2 at 37C
for 24 hours. Next, a culture was prepared by incubating
colonies in 40 mL of Luria-Bertani broth that contained 0.5%
glycerol (and antibiotics when appropriate) and shaken at 200
rpm overnight at 27C. A subculture was then prepared by
transferring an aliquot of the overnight culture to fresh NBY-
NaHCO3 at a starting OD600 of 0.1 and placed in a shaking
incubator of 10% CO2 at 37C for approximately 3 to 4 hours
until reaching an OD600 of 1.2 and then centrifuged, washed
with Dulbecco’s PBS, and diluted with Dulbecco’s PBS to
the ﬁnal inoculum concentration. Inoculums were veriﬁed by
diluting and plating on sheep blood agar plates to obtain the
actual concentration.
Animals
All animal work was performed at the Lovelace Respiratory
Research Institute (LRRI) in a facility fully accredited by the
International Association for the Assessment and Accredi-
tation of Laboratory Animal Care. All procedures were per-
formed in accordance with the guidelines promulgated in the
Guide for the Care and Use of Laboratory Animals (National
Research Council, Washington, DC) and approved by the
Institutional Animal Care and Use Committee at the LRRI.
All animals were provided with approved environmental
enrichment during the study. All animals were determined to
be healthy before initiation of experimental procedures based
on physical examination and evaluation of prestudy hema-
tologic and clinical chemical test results.
Juvenile to adult (1.3 to 7.3 kg; males and females) Viet-
namese cynomolgus macaques were obtained from Covance
Research Products (Alice, TX). All animals were tuberculin
skin test negative and seronegative for Cercopithecine
herpesvirus 1 (B virus), simian retrovirus, simian immuno-
deﬁciency virus, simian T-lymphotropic virus, and simian
foamy virus. On arrival at the LRRI, animals were quarantined
for 30 days before housing in individual cages in the biosafetyThe American Journal of Pathology - ajp.amjpathol.orglevel 3 facility. Animals had contact with cohorts through
allogrooming panels in cages and were fed a commercial
primate diet (Global Primate Diet 2050; Harlan Teklad,
Madison, WI) supplemented with fresh fruits and vegetables.
Animals were maintained on a 12:12-hour light:dark cycle and
provided with a variety of enrichment devices to promote
psychological well-being. Details regarding individual ani-
mals are given in Supplemental Table S1.
Anthrax Challenge
Exposures were performed for several months by trained
personnel in an animal biosafety level 3 containment area.
Animals were typically challenged serially in small groups
(1 to 3 per strain per dose), and lethality data from the pre-
ceding challenge with a given strain and dose route were used
to determine the doses for subsequent challenges to minimize
the total number of animals used. For intrabronchial chal-
lenges, anesthesia was induced using 10 mg/kg of intra-
muscular ketamine, followed by intubation and maintenance
of anesthesia with 3% isoﬂurane. A pediatric bronchoscope
(BFXP40; Olympus America, Center Valley, PA) was passed
through the endotracheal tube into the right mainstem bron-
chus, just distal to the carina. A 1-mL spore aliquot was
introduced through the bronchoscope into the lung, followed
by rinsing with a 1-mL aliquot of sterile PBS and injection of
10 mL of air. The bronchoscope was removed from the right
lung and repositioned in the left mainstem bronchus, just
distal to the carina, and the procedure was repeated. De-
positions of the aliquots into the lungs were veriﬁed by visual
conﬁrmation using the bronchoscope video camera feature.
The actual dose delivered for each spore preparation was
calculated by averaging the doses delivered in three mock
inoculations, whereby the spore aliquots were collected and
cultured after passing through the bronchoscope. Animals
were challenged with the different strains of B. anthracis on
different days, and the bronchoscope was sterilized between
strains. For i.v. challenges, animals were anesthetized with
10 mg/kg of intramuscular ketamine, and 1-mL aliquots of
vegetative bacilli were delivered slowly (for 1 minute) by i.v.
injection into the cephalic vein.
Postchallenge Monitoring and Determination of
Lethality
Animals were monitored after challenge by trained techni-
cians in consultation with the clinical veterinary staff.
Monitoring included at least twice-daily evaluation of ac-
tivity level, mentation, appetite, and temperature measure-
ment using subcutaneous microchips. During the ﬁrst 7 days
after challenge, blood was collected daily from animals
conditioned to primate chairs for qualitative bacterial culture,
hematologic analysis, and limited clinical chemistry assays
(alanine aminotransferase, total protein, blood urea nitrogen,
lactate dehydrogenase, and C-reactive protein). Hematology
measurements were performed using an Advia120 (Bayer3207
Figure 1 Survival of cynomolgus macaques after bronchoscopic
delivery of varying doses of Ames strain Bacillus anthracis spores.
Animals were monitored for 21 days after challenge, and animals still
alive at study termination on day 21 were considered to be survivors.
Individual animal identiﬁcation numbers are provided to the right of
each bar, and the details regarding individual animals are listed in
Supplemental Table S1.
Hutt et alCorporation, Diagnostic Division, Tarrytown, NY), and
clinical chemistry measurements were performed using a
Hitachi 911 chemistry analyzer (Roche Diagnostics, Indi-
anapolis, IN). Thereafter, blood was collected weekly for the
same assays until study termination on day 14 or 21. For the
animals dosed with spores by bronchoscopy, survival was
monitored for 21 days with the exception of the three animals
challenged with the PA deletion mutant, which were eutha-
nized on day 14. The animals given vegetative bacilli by the
i.v. route were monitored for 14 days. Animals euthanized at
study termination and animals determined to be moribund
during the clinical observation period were euthanized by i.v.
overdose of sodium pentobarbital. The LD50 values were
determined using logistic regression analysis (SAS statistical
software version 9.3; SAS Institute Inc, Cary, NC) with 95%
conﬁdence intervals.
Necropsy and Histologic Analysis
Necropsies were performed on all animals immediately
after euthanasia or within 12 hours of death. Gross lesions
were recorded, and samples were collected for bacterio-
logic and histopathologic analysis. Samples collected for
bacteriologic analysis included blood (before moribund
euthanasia only), tracheobronchial lymph node (TBLN),
right middle lung lobe, spleen, and liver. Samples placed in
10% neutral-buffered formalin for histologic analysis
included TBLN, spleen, liver, brain, and formalin-infused
lungs. Tissues were ﬁxed for approximately 14 days,
trimmed, and processed routinely, and 5-mm tissue sections
were stained with H&E and/or Brown and Brenn stain for
histopathologic analysis by a board-certiﬁed veterinary
pathologist (J.A.H.).
Qualitative Blood Culture
Shortly after collection, blood collected into EDTA tubes
was plated onto tryptic soy agar (TSA) plus sheep blood
using a standard quadrant streak method. To culture any
bacteria potentially present in low numbers and not detect-
able using the quadrant streak method, an aliquot (250 mL)
was removed and placed into 5 mL of sterile tryptic soy
broth. Tryptic soy broth samples were allowed to incubate at
37C  2C for 24 to 48 hours, after which the broth was
thoroughly mixed and qualitatively processed as described
for the EDTA blood samples above. TSA plus sheep blood
plates were incubated at 37C  2C for 18 to 24 hours,
after which B. anthracis presence and purity were visually
assessed.
Quantitative Tissue Culture
Tissue collected at necropsy was placed in 5 mL of sterile
1% peptone in tared 50-mL vials and weighed. Tissue
samples were individually processed using sterile disposable
tissue grinders. Processed tissue suspensions were serially3208diluted in sterile 1% peptone. From select dilutions, 100-mL
aliquots were removed and spread onto sterile 90-mm TSA
plates in triplicate (300 mL total for each dilution). TSA
plates were incubated at 37C  2C for 18 to 24 hours,
after which purity was visually assessed and B. anthracis
colonies were counted. In some instances after standard
culture, aliquots of processed lung and TBLN samples were
heat shocked in a 65C water bath for 30 minutes, diluted,
and plated as already described to quantify spores. For
coinfection studies that used a combination of wild-type
(WT) and PA strains, aliquots of organ homogenates
were plated on agar plates both with and without 50 mg/mL
of kanamycin to distinguish the number of PA (kanamycin
resistant) organisms from WT organisms.Results
Bronchoscopic delivery of B. anthracis spores to cyn-
omolgus macaques results in lethality and target organ
disease comparable to aerosol delivery. Bronchoscopy was
used to deliver different doses of B. anthracis spores
directly into the lungs of cynomolgus macaques. Bron-
choscopic delivery of spores was used instead of aerosol
delivery to better control the challenge doses and exclude
the confounding effects of spore uptake and germination in
the nasal cavity and gastrointestinal tract, thereby facili-
tating a more precise comparison of Ames parent strain
with each of the toxin deletion mutants. The survival of
cynomolgus macaques challenged with varying doses of B.
anthracis Ames strain spores is shown in Figure 1, and
details regarding individual animals are provided in
Supplemental Table S1. All animals challenged with >105
spores died, and all animals challenged with <104 spores
survived until study termination on day 21 after challenge.
Between 104 and 105 spores, 2 of 5 animals died, which is
consistent with the reported LD50 of approximately 6 104
spores for cynomolgus macaques after aerosol challenge
with Ames spores.32 Animals receiving higher doses ofajp.amjpathol.org - The American Journal of Pathology
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receiving lower doses (Figure 1). Overall, there were no
apparent differences in survival days between males and
females.
Lesions in target organs (lung, TBLNs, liver, spleen, and
brain) were evaluated in animals that succumbed to anthrax
after bronchoscopic delivery of Ames strain spores. Lesions
were comparable to those reported after aerosol challenge,32
and there was no gross or microscopic evidence of
bronchoscope-induced trauma to the conducting airways or
lungs. Large bacilli were detected within the vessels ofFigure 2 Terminal target organ lesions in cynomolgus macaques chal-
lenged with Ames strain Bacillus anthracis by bronchoscopy are similar to
those observed after inhalation of aerosolized spores. Terminal lesions were
similar regardless of inoculum dose or time to death. Sections were stained
with H&E (AeD) and Brown and Brenn stain (EeH). A and E: Alveolar septa
in the lungs are distended with bacilli. B and F: Bacilli in the subcapsular
sinus and cortex of a tracheobronchial lymph node, with cortical lympho-
cytolysis. C and G: Numerous bacilli in the splenic red pulp. D and H: Bacilli
with scattered neutrophils in the hepatic sinusoids. Arrows point to bacilli.
Original magniﬁcation: 400 (AeH).
Figure 3 Meningeal hemorrhage in a cynomolgus macaque that suc-
cumbed after bronchoscopic delivery of Ames strain Bacillus anthracis.
Arrow points to a focus of meningeal hemorrhage in the occipital cortex.
The American Journal of Pathology - ajp.amjpathol.orgmany organs (Figure 2). Lung lesions consisted of wide-
spread edema and hemorrhage with infrequent small foci of
neutrophilic alveolitis. The TBLN lesions consisted of
multifocal, ﬁbrinosuppurative to necrotizing inﬂammation in
the cortex, paracortex, and medullary cords with variable
lymphocytolysis (Figure 2B). Splenic lesions consisted of
suppurative to necrotizing inﬂammation in the red pulp with
lymphocytolysis in the white pulp (Figure 2C). Liver lesions
primarily consisted of accumulation of neutrophils and
necrotic or apoptotic cell debris within sinusoids (Figure 2D),
although occasional foci of coagulation necrosis were also
observed in a few animals. Other lesions included hemor-
rhage, edema, and mild neutrophilic inﬂammation within the
mediastinum and hemorrhage within the meninges (Figure 3)
and adrenal cortex. Target tissues from animals that survived
until study termination on day 21 were also cultured and
examined histologically and found to be without detectable
bacteria or lesions.
LT, but Not ET, Is Essential for Development of Fatal
Anthrax after Bronchoscopic Spore Delivery
The LD50 values for spores of the WT Ames strain and each
of the toxin deletion mutants after bronchoscopic challenge
of cynomolgus macaques are given in Table 1. Delivery of up
to 9  107 spores of the LF and PA deletion mutants was
insufﬁcient to induce mortality in cynomolgus macaques. In
contrast, animals dosed with the EF deletion mutant suc-
cumbed in an inoculum dose-dependent manner (Figure 4).
At the lower end of the dosing range (4 to 7  103 spores),
spores of the EF deletion mutant were more lethal than spores
of the Ames parental strain. Lesions in target organs of the
animals that succumbed after challenge with the EF deletion
mutant were similar to those observed in the animals3209
Table 1 LD50 Values for Ames and Isogenic Mutant Strains After
Pulmonary Challenge with Spores in Cynomolgus Macaques
Strain Genotype
Means  SEM LD50*
(log10) 95% CI (log10)
Ames WT 4.13  0.02 3.83e4.42
EF cya 3.40  0.18 2.56e4.23
LF lef >7.9y NA
PA pagAR >7.9y NA
Groups of NHPs were challenged by bronchoscopy with Bacillus anthracis
spores of either the Ames strain (WT) or the EF, LF, or PA strain at
doses ranging from 102 to 108 spores per NHP for the WT and EF strains
(nZ 3 to 5 NHP per dose per strain) and 105 to 108 spores per NHP for the
LF and PA strain (nZ 3 to 6 NHP per dose per strain). The NHPs were
monitored twice daily for survival and clinical observations during
infection.
*The LD50 values for the Ames or the EF strains in the NHPs were
determined using logistic regression analysis and were found to be
signiﬁcantly different (z Z 4.03, P < 0.0001).
yAll animals inoculated with the highest challenge dose tested of 9  107
spores per NHP of the LF or PA strains survived.
EF, edema factor; LF, lethal factor; NA, not applicable; NHP, nonhuman
primate; PA, protective antigen; WT, wild type.
Figure 4 Survival of cynomolgus macaques after bronchoscopic de-
livery of varying doses of Bacillus anthracis edema factor deletion mutant
spores. Animals were monitored for 21 days after challenge, and animals
still alive at study termination on day 21 were considered to be survivors.
Individual animal identiﬁcation numbers are provided to the right
of each bar, and the details regarding individual animals are listed in
Supplemental Table S1.
Hutt et alchallenged with the parental Ames strain spores with bacilli
detected in multiple organs (data not shown). Target tissues
from animals that survived until study termination on day 21
after bronchoscopic challenge with the EF deletion mutant
were cultured and examined histologically and found to be
without detectable bacteria or lesions.
Although the animals challenged with the LF and PA
deletion mutants survived the challenge, they developed mild
clinical disease, characterized by decreased appetite and ac-
tivity level and development of a mild, dry cough during the
ﬁrst week to 10 days after challenge. Elevations in C-reactive
protein and peripheral blood neutrophil counts were detected
during a 2- to 3-week period of observation, indicating the
development of an inﬂammatory response to the LF and PA
deletion mutants (Figure 5). A low-level transient bacteremia
was detected in a few animals during the ﬁrst 7 days after
challenge (Figure 5), indicating that the spores were able to
germinate and bacilli were able to escape from the thoracic
cavity at low levels despite the deletion of LF and PA. At the
time of study termination, however, the lungs, TBLNs, liver,
and spleen from several of these animals were cultured, and
B. anthraciswas detected only in the lungs (approximately 105
CFU/g in animals challenged with >107 spores and <103
CFU/g in animals challenged with 105 spores) and TBLNs
(approximately 103 CFU/g in animals challenged with >107
spores and <102 CFU/g in animals challenged with
105 spores).
In six of the animals challenged with the LF deletion
mutant, aliquots of lung and TBLN culture samples were heat
shocked in a 65C water bath for 30 minutes before culture
initiation. Essentially all the bacteria cultured from these
samples were heat resistant, suggesting that the residual
bacteria were present as spores. Microscopic evaluation of
lungs collected at study termination from the animals3210challenged with the LF and PA deletion mutants revealed the
presence of a dose-dependent chronic granulomatous pneu-
monia on days 14 (PA deletion mutant) and 21 (LF deletion
mutant) after challenge, presumably in response to the
presence of residual spores in the lungs (Figure 6). The
draining lymph nodes of the animals challenged with the LF
and PA deletion mutant spores exhibited lymphoid hyper-
plasia with prominent germinal center formation. No signif-
icant lesions were detected in the liver, spleen, or brain of any
of these animals, and there were no detectable bacteria in
these tissues.LT Contributes More to B. anthracis Virulence than ET
in a Systemic Model of Infection with Vegetative
Bacilli
B. anthracis spores that lack LT were unable to cause high
levels of bacteremia and death in cynomolgus macaques
after bronchoscopic delivery. To bypass the lungs and
draining lymph nodes and evaluate the role of toxins during
the systemic phase of anthrax, cynomolgus macaques were
challenged by i.v. injection (cephalic vein) with vegetative
forms of the Ames strain and each of the respective toxin
deletion mutants. The survival of cynomolgus macaques
after i.v. challenge with different doses of each of the strains
is given in Table 2. The Ames and EF deletion mutants were
uniformly lethal within 2 to 3 days after challenge at all i.v.
doses examined. Cynomolgus macaques survived i.v. doses
of up to 5.8  104 CFU (target dose was 1  105 CFU) of
the LF deletion mutant bacilli and up to 1.3  106 CFU of
the PA deletion mutant bacilli. The i.v. doses of 106 CFU
of the LF deletion mutant bacilli and 107 CFU of the PA
deletion mutant bacilli were required to cause lethality in
cynomolgus macaques, again within 2 to 3 days after
challenge.
It was possible that the mechanism of death after i.v.
challenge might be different in the animals that died fromajp.amjpathol.org - The American Journal of Pathology
Figure 6 Chronic granulomatous pneumonia in a cynomolgus macaque
21 days after bronchoscopic challenge with 107 spores of the lethal factor
deletion mutant. Sections were stained with H&E. Lesion severity was dose
dependent and also present in the animals challenged with the PA deletion
mutant. Arrows point to foci of granulomatous inﬂammation. Original
magniﬁcation: 40 (A); 200 (B).
Lethal Factor Required for Anthraxthe LT-producing (Ames and EF deletion mutant) virulent
organisms compared with the high doses of markedly
attenuated LT-nonproducing strains (LF and PA deletion
mutants). In general, the macroscopic and microscopic
ﬁndings in the monkeys that died after i.v. challenge with
the EF and LF deletion mutant bacilli were similar to those
in monkeys that died after intrabronchial and i.v. challenge
with the Ames strain. This ﬁnding suggests that the patho-
logic ﬁndings associated with terminal anthrax does not
depend on the presence of a speciﬁc toxin. However, one of
the monkeys that succumbed to the LF deletion mutant
exhibited extensive suppurative meningoencephalitis
microscopically. Likewise, the single monkey that suc-
cumbed to the PA deletion mutant also exhibited extensive
suppurative meningoencephalitis (Figure 7). This lesion
was not observed in any of the other monkeys described in
this study. There were no other signiﬁcant macroscopic or
microscopic ﬁndings in the single monkey that died from
the high challenge with the PA deletion mutant (Figure 7). ItFigure 5 Inﬂammatory response in cynomolgus macaques after bron-
choscopic delivery of spores of Bacillus anthracis lethal factor (LF, two
dose levels) and protective antigen (PA, one dose level) deletion mu-
tants. Elevations in C-reactive protein (CRP) (A and C) and peripheral blood
neutrophil counts (B, D, and E) were identiﬁed after challenges. At each
dose level, the CRP levels and neutrophil counts are given for the same
three animals. For the animals challenged with spores of the PA deletion
mutant, there was insufﬁcient serum to assay CRP on each day after
challenge. The mean CRP level on day 4 is reported below the neutrophil
graph for these three animals. Asterisks (B, D and E) indicate the days on
which bacteremia was detected in speciﬁc animals.
The American Journal of Pathology - ajp.amjpathol.orgis also noteworthy that the terminal bacterial burdens in the
lungs, liver, spleen, and TBLNs were similar in monkeys
that succumbed after lethal i.v. doses of Ames strain and the
EF and LF deletion mutants, but the terminal tissue burdens
for the single animal that succumbed to the highest i.v. dose
of the PA deletion mutant were 103 to 105 lower in each of
the tissues that were cultured (Table 3). This latter animal
that succumbed to the highest i.v. dose of the PA deletion
mutant, but had the lowest bacterial burden in the lungs,
liver, spleen, and TBLNs, was one of the two monkeys that
developed suppurative meningoencephalitis.PA Deletion Mutants Are Cleared More Rapidly than
Ames in a Systemic Model of Infection with Vegetative
Bacilli
Previously, we co-infected New Zealand white rabbits
with approximately equal inoculums of Ames and the PA
deletion mutant with spores via bronchoscopy or with
vegetative bacilli via i.v. injection and found that the
toxins produced by the Ames strain organisms did not
increase dissemination or systemic survival of the PA
deletion mutant organisms compared with levels seen in
rabbits challenged with the PA deletion mutant alone.29
To begin to examine whether the same was true in mon-
keys, we intravenously injected three cynomolgus ma-
caques with a mixture of bacilli that contained
approximately equal inoculums of Ames and PA deletion
mutant bacilli and euthanized the animals after 24 to 25
hours to quantitatively culture the lungs, spleen, and liver.
The results are given in Table 4. Of the two monkeys that
received 104 CFU of each strain, both appeared to be
clearing or controlling the proliferation of the PA deletion
mutant bacilli better than the Ames bacilli. A third mon-
key dosed intravenously with approximately 106 CFU of
each strain and euthanized at 24 to 25 hours after infection
had a similar pattern to the ﬁrst two monkeys. Of note,
none of these monkeys were clinically ill at the time of
euthanasia. A fourth monkey was dosed intravenously
with 105 CFU each of Ames and PA deletion mutant3211
Figure 7 Suppurative meningoencephalitis in a cynomolgus macaque
succumbing to i.v. delivery of 107 CFU of protective antigen deletion
mutant bacilli. Sections were stained with H&E. Lesions were not apparent
in lungs (A), tracheobronchial lymph nodes (B), spleen (C), or liver (D). E
and F: The brain and meninges exhibited marked suppurative meningoen-
cephalitis (arrows) with abundant bacilli. Original magniﬁcation: 200
(AeD and F); 20 (E).
Table 2 Survival of Cynomolgus Macaques after Intravenous
Challenge with Vegetative Bacilli of the Ames Strain and Each of
the Toxin Deletion Mutants
Log10 dose
(range)
Surviving animals by strain
(no. surviving/no. challenged)
Ames EF LF PA
3e4 ND 0/1 ND ND
4e5 0/1 0/2 3/3 ND
5e6 0/1 ND ND ND
6e7 0/1 ND 0/2 2/2
7e8 ND ND 0/1 0/1
ND, not done.
Hutt et albacilli and monitored until clinical signs of disease
developed. This monkey was euthanized at 30.5 hours
after infection after exhibiting reduced activity, increased
respiratory rate, and discolored red urine consistent with
being near death. The tissue burdens of both Ames and the
PA deletion mutant were higher than their initially injec-
ted inoculums. However, the tissue bacterial burdens of
the Ames strain were still several orders of magnitude
higher than for the PA deletion mutant and were similar to
the terminal organ bacterial burdens found post mortem in
monkeys previously challenged with the Ames strain
alone (Table 3).
Discussion
Understanding the roles of LT and ET in the species that are
used to model inhalational anthrax in humans is important for
developing new vaccines and therapeutic countermeasures
against anthrax. Thus, we assessed the role of B. anthracis
LT and ET in cynomolgus macaques using speciﬁc toxin
deletion mutants created from the pX01þ and pX02þ Ames
strain of B. anthracis. In cynomolgus macaques, LT was
required for sustained bacteremia and death after pulmonary
challenge with spores and was the major toxin required to
cause a lethal infection after i.v. delivery of vegetative bacilli.
This dependence on LT for developing disseminated anthrax
after respiratory tract challenge with spores is similar to what
has been reported in A/J mice challenged by aerosol with
toxin deletion mutants of the a capsular Sterne strain of
anthrax35 but is in contrast to the rabbit model where the
Ames mutant expressing ET alone is as capable of causing
disseminated anthrax as the mutant expressing LT alone,
albeit at higher doses than the WT parental strain.29 In cyn-
omolgus macaques, deletion of EF in the presence of LT
resulted in even greater lethality than the Ames strain spores
after pulmonary challenge. This unexpected result may be
due to greater production of LF in the absence of EF or may
indicate that the absence of EF permits greater binding of LF
to PA and hence greater LT activity in the early stages after
spore germination. Interestingly, the greater lethality of
mutants expressing LT alone was not apparent in the rabbit
model.29 Deletion of PA eliminated the effects of both ET3212and LT and resulted in complete loss of lethality after
bronchoscopic challenge of cynomolgus macaques with
spores and markedly reduced virulence in the i.v. bacilli
model. In contrast to LT, ET expression alone did not allow
for sustained bacteremia and death after pulmonary spore
challenge, and it contributed only minimally to lethality after
i.v. challenge with high doses of bacilli.
Importantly, both the LF and PA deletion mutants were
capable of causing infection after bronchoscopic challenge
even though the infection was not fatal. Cynomolgus
macaques challenged with >6  105 spores of the LF
and >9  107 spores of the PA deletion mutants exhibited
mild clinical signs of illness and dose-dependent, chronic
lung inﬂammation at the time of study termination 14 to 21
days after challenge. Cultures revealed that some bacteria,
presumably spores, were present in the lungs and TBLNs at
study termination. Peripheral blood neutrophil counts and
serum C-reactive protein levels measured at several time
points after challenge indicated an inﬂammatory response to
the bronchoscopically delivered LF and PA deletion mutant
spores, and blood cultures performed daily during the ﬁrst
week after challenge revealed transient, low-level bacter-
emia in several animals. The enlarged TBLNs with promi-
nent germinal centers identiﬁed at study termination
suggested that an adaptive immune response developedajp.amjpathol.org - The American Journal of Pathology
Table 3 Quantitative Bacterial Cultures from Tissues of Cynomolgus Macaques Lethally Challenged by the I.V. Route with Bacilli of the
Ames Strain and Each of the Toxin Deletion Mutants
Group Animal no. Death day I.V. dose (CFU)
Concentration (CFU/g)
Spleen Liver TBLN Lung
Ames V1 2 2.2  104 5.0  108 3.1  108 1.4  108 7.1  108
V2 2 2.1  105 1.2  108 1.5  108 3.8  107 4.2  108
V3 2 2.2  106 4.3  107 9.4  107 1.9  107 3.6  107
EF V4 1 2.2  103 3.0  107 1.2  108 4.4  106 3.2  108
V5 3 2.7  104 2.8  107 2.1  107 1.3  106 3.1  107
V6 3 2.7  104 4.9  108 2.1  108 1.1  108 2.5  108
LF V10 3 1.4  106 2.0  108 2.7  107 3.0  106 3.5  108
V11 2 1.4  106 2.2  107 1.8  105 1.3  107 2.8  107
V12 2 1.4  107 9.6  107 9.7  106 5.2  107 2.3  107
PA V15 2 1.3  107 2.7  104 3.3  102 1.0  102 1.2  105
Cultures were initiated at the time of necropsy, between 2 and 12 hours after death.
EF, edema factor; LF, lethal factor; PA, protective antigen; TBLN, tracheobronchial lymph node.
Lethal Factor Required for Anthraxafter challenge, and it is possible that these animals might be
immune to a subsequent challenge with virulent spores.
Indeed, one might predict that the LF deletion mutant
capable of making PAwould be more protective than the PA
deletion mutant.
On the basis of available data about anthrax and the
B. anthracis toxins, Tournier et al1 proposed a model of
inhalational anthrax pathogenesis in which the toxins exert
local effects on lung macrophages and dendritic cells during
the invasion and proliferation phases in the lungs and
draining lymph nodes and systemic effects on endothelial
cells and the cardiovascular system during the terminal
bacteremic phase of the disease. In agreement with this
proposed model, our data suggest that LT functions as a
virulence factor, facilitating proliferation and/or survival of
germinated bacilli in the pulmonary lymphatics and draining
lymph nodes after pulmonary challenge. In addition, LT,
and to a lesser extent ET, contributes to bacillus survival and
proliferation systemically in cynomolgus macaques after i.v.
challenge. The question then arises of whether LT plays an
additional, more direct role in killing the host, as has been
suggested by studies using animal models challenged with
puriﬁed toxins.
Despite clear evidence of the ability of both puriﬁed LT
and ET to cause death in rats and mice,8,9,23,36,37 theTable 4 Quantitative Bacterial Cultures from Tissues of Cynomolgus Ma
Ames Strain and the PA Deletion Mutant
Animal no.
Time to
euthanasia (h)
I.V. dose (CFU)
Concentration
Lung
Ames PA WT
V16 24.5 6.0  104 4.0  104 1.5  104
V17 25.0 6.0  104 4.0  104 BLD
V18 24.5 8.0  105 1.8  106 BLD
V19* 30.5 1.0  105 1.0  105 5.3  108
*V19 was the only monkey of this group with clinical signs related to anthrax
BLD, below limit of detection; PA, protective antigen; WT, wild type.
The American Journal of Pathology - ajp.amjpathol.orgrelevance of experimental animal exposures to a parenteral
bolus of puriﬁed toxins for studying the effects of toxins
during the terminal, septicemic phase of anthrax is uncer-
tain. Clearly, the use of puriﬁed toxins disregards the
complex interplay between the bacilli and the host immune
response. In addition, there are uncertainties about the
relevance of the dose of puriﬁed toxins used in the rodent
studies and whether a bolus dosing protocol better enables
the toxins to overwhelm potential detoxiﬁcation and
excretion mechanisms of the host. Recently, in studies using
New Zealand rabbits and rhesus macaques, the serum con-
centration of toxin components was found to increase
gradually between 2 and 4 days after spore challenge.38e40
Paradoxically, in both species the individual animals with
the highest serum toxin concentrations on day 2 were the
animals that survived the longest, indicating that the toxin
levels during a natural infection are controlled by complex
mechanisms. Furthermore, the recent identiﬁcation of a
putative serum protease that cleaves PA and results in loss
of LT activity highlights the complexities and potential for
species differences in susceptibility to anthrax toxins.39
Although identiﬁed in both mouse and human sera, the
human protease had greater activity than the mouse prote-
ase, and the amount of protease activity in human sera
varied for different individuals, leading the authors tocaques Challenged by the I.V. Route with Mixtures of Bacilli of the
(CFU/g)
Spleen Liver
PA WT PA WT PA
4.1  103 4.2  105 2.4  103 1.4  104 BLD
BLD 6.0  103 5.8  102 3.0  103 BLD
BLD 8.5  103 8.2  102 BLD BLD
6.0  105 >1.5  109 4.5  107 1.2  109 2.2  107
at the time of euthanasia.
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Hutt et alspeculate that variations in protease activity may contribute
to individual susceptibility to systemic anthrax toxins in
humans.
The role of anthrax toxin in killing rhesus macaques was
previously investigated.41 Injection of in vitro produced
toxin revealed that anthrax toxin alone was sufﬁcient to kill
rhesus macaques. However, the amount of toxin used was
speciﬁed in terms of minutes to death of a rat, a species
highly susceptible to anthrax toxins but highly resistant to
anthrax, so the precise amount of LT and ET delivered is
unknown. In addition, considering the likely existence of a
toxin-neutralizing serum protease in NHP serum, a bolus
dose of toxin might be expected to overwhelm the protease
activity more so than the gradual increase in toxin observed
during the septicemic phase of anthrax. Interestingly, in
rhesus macaques dying of anthrax after challenge with
spores, not all animals had detectable toxemia near the time
of death.
Results from our study suggest that the primary effect of
LT during the systemic bacteremic phase is to facilitate
survival and proliferation of vegetative bacteria. In addi-
tion, the presence of similar pathologic ﬁndings and similar
terminal bacterial burdens in the animals that died after i.v.
challenge with Ames and the LF and EF deletion mutants
suggests that death from anthrax is not toxin speciﬁc but
may be due to the high level of bacteremia, which has
recently been proposed in the literature.42 The absence of
LT in the LF and PA deletion mutants presumably permits
survival of the phagocytic cells that are required for
clearance of the bacilli from the circulation. The low ter-
minal bacterial burdens in the tissues of the animal that
succumbed to challenge with a bolus i.v. dose of 107 CFU
of the PA deletion mutant indicate that the host was still
able to control bacterial proliferation to some extent, pre-
sumably because of the preserved viability of its phago-
cytic cells. This animal likely succumbed because of the
inability of the liver and spleen to effectively remove such
a large number of bacilli delivered as a single i.v. bolus.
The bacilli that escaped clearance seeded the meninges and
established a suppurative meningoencephalitis, explaining
death in the absence of a substantial bacterial burden in
other organs. Notably, neutrophilic meningoencephalitis
was identiﬁed in one of the monkeys that succumbed to the
LF deletion mutant after i.v. delivery of 106 CFU of bacilli.
The recently identiﬁed plasmid-encoded (pX01) adhesion
protein B. anthracis S-layer protein A, which has been
found to mediate attachment to brain microvascular
endothelial cells and disrupt the tight junction proteins,
may have contributed to the development of meningoen-
cephalitis in the absence of LF or PA.43,44 The slight dif-
ference in survival between the monkeys challenged with
high i.v. doses of the LF deletion mutant compared with
the PA deletion mutant (Table 2), along with the higher
terminal tissue burdens for monkeys challenged with the
LF deletion mutants (Table 3), suggests that ET alone has a
slight role as a virulence factor during the systemic phase3214of infection, although the exact nature of that role was not
clear in these experiments.
In the ﬁnal experiment in which cynomolgus macaques
were challenged with an i.v. mixture of approximately equal
numbers of Ames and PA deletion mutant bacilli, the tissue
bacterial burdens for the PA deletion mutant were substan-
tially lower than for the Ames strain at 24 to 25 hours after
challenge and immediately before the anticipated death of the
animal. These data indicate that host defenses were better
able to control the growth of the PA deletion mutant
compared with the Ames bacilli and are similar to our results
in rabbits in that regard.29 In addition, these results suggest
that even during the disseminated stage of anthrax, the toxin
may exert its function in close proximity to the bacillus that
secreted it. However, in the monkey that was euthanized with
clinical signs indicating impending death, there was clear
evidence of proliferation of both the Ames and PA deletion
mutants above the initial inoculum based on the bacterial
tissue burdens detected. The proliferation of the PA deletion
mutant above the initial inoculum levels in this monkey may
have been the result of i) the very large numbers of Ames
bacilli and hence the systemic presence of the Ames toxins,
allowing survival and proliferation of the mutant bacilli; ii)
phagocyte death and depletion induced by the Ames-derived
LT; and iii) nonspeciﬁc Ames-induced clinical illness rather
than a speciﬁc response to Ames toxin production.
Our data together with data from other studies are
compatible with B. anthracis LT playing a major role in the
pathogenesis of inhalational anthrax by suppressing the
innate immune response, thereby facilitating the survival
and proliferation of the organism within the lung and
draining lymph nodes and ultimately in target organs and
the systemic circulation. ET has a lesser role as a virulence
factor, and its role in the cynomolgus macaque is limited to
the systemic phase of anthrax. These results are signiﬁcant
in that they suggest LT is likely to be the more relevant
toxin target for new vaccines and therapeutics against
inhalational anthrax in humans. In addition, therapeutics
targeting ET activity alone, particularly in the early stages
after challenge with spores, may enhance bacterial viru-
lence. Our results are also consistent with the sepsis model,
suggesting the death in cases of inhalational anthrax is a
result of the high-level bacteremia.Acknowledgments
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